Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 274,297 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 274,297 shares of Dyne Therapeutics stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $19.52, for a total transaction of $5,354,277.44. Following the completion of the transaction, the director directly owned 13,148 shares of the company’s stock, valued at $256,648.96. The trade was a 95.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Up 2.4%

DYN opened at $19.67 on Thursday. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25. The company has a fifty day moving average of $17.58 and a two-hundred day moving average of $18.36. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of -5.56 and a beta of 1.29.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). On average, research analysts expect that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DYN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday. Wall Street Zen cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. HC Wainwright cut their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Finally, JPMorgan Chase & Co. cut their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Institutional Trading of Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Pictet Asset Management Holding SA increased its stake in shares of Dyne Therapeutics by 49.4% during the first quarter. Pictet Asset Management Holding SA now owns 19,372 shares of the company’s stock worth $351,000 after purchasing an additional 6,409 shares in the last quarter. Wasatch Advisors LP increased its stake in shares of Dyne Therapeutics by 9.0% during the first quarter. Wasatch Advisors LP now owns 443,668 shares of the company’s stock worth $8,044,000 after purchasing an additional 36,708 shares in the last quarter. Hilton Head Capital Partners LLC acquired a new position in Dyne Therapeutics during the first quarter worth about $26,000. Rockefeller Capital Management L.P. boosted its position in Dyne Therapeutics by 67.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 14,268 shares of the company’s stock worth $279,000 after acquiring an additional 5,730 shares during the last quarter. Finally, Seven Fleet Capital Management LP acquired a new position in Dyne Therapeutics during the fourth quarter worth about $1,373,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.